Loading…

Design and synthesis of structurally identical coumarinotriazoles as cytotoxic and antimicrobial agents

Novel coumarinotriazoles have been synthesized with excellent yield by 1,3-cycloaddition reaction of substituted coumarin azides with active methylene compounds using sodium hydride. Synthesized compounds were screened for their in vitro anticancer activity against HEP-G2 and MCF-7 cell lines using...

Full description

Saved in:
Bibliographic Details
Published in:Chemical Data Collections 2018-12, Vol.17-18, p.219-235
Main Authors: Madar, Jyoti M., Shastri, Lokesh A., Shastri, Samundeeswari L., Guda, Ramu, Holiyachi, Megharaja, Naik, Nirmala S., Dodamani, Suneel, Jalapure, Sunil, Sungar, Vinay A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Novel coumarinotriazoles have been synthesized with excellent yield by 1,3-cycloaddition reaction of substituted coumarin azides with active methylene compounds using sodium hydride. Synthesized compounds were screened for their in vitro anticancer activity against HEP-G2 and MCF-7 cell lines using Cisplatin as reference drug. Most of the compounds from series 3 and 4 are highly active against MCF-7 with IC50 value ranges from 1.56 to 6.25 µg/mL. Among, compounds 3c, 4b, 4e and 5e showed excellent cytotoxicity against HEP-G2 with IC50 value 1.56 µg/mL over the standard Cisplatin. Further, screened for their in vitro antibacterial activity against S.aureus, B.subtilis, E.coli and P.aeruginosa bacterial strains, whereas antifungal activity against C.albicans and A.niger by broth dilution technique. Compounds 3a, 3b, 3d, 4c, 4d, 4f, 5d, 5e, and 5f showed promising activity against S.aureus. The detailed study about molecular interaction with targeted protein MurB were performed by using docking stimulations and obtained results are quite promising. [Display omitted]
ISSN:2405-8300
2405-8300
DOI:10.1016/j.cdc.2018.09.005